“BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety” (2025) Prospects in Pharmaceutical Sciences, 23(1), pp. 31–46. doi:10.56782/pps.292.